Med24
peptide-development 1. 10. 2026 • 2 min read • Journal of managed care & specialty pharmacy

Real-world treatment patterns and cost per patient achieving treatment targets among tirzepatide and semaglutide initiators in US patients with type 2 diabetes

Background Tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist (RA), and semaglutide, a GLP-1 RA, are approved for type 2 diabetes (T2D) management. Clinical trials demonstrated that tirzepatide provided greater hemoglobin A1c and weight reduction vs...

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

This retrospective cohort study examined real-world treatment patterns for type 2 diabetes (T2D) patients initiating tirzepatide (Mounjaro) or semaglutide (Ozempic) from May 2022 to May 2023. The analysis utilized claims and laboratory data from the Healthcare Integrated Research Database. The study compared adherence, persistence, and treatment outcomes in patients stratified by prior GLP-1 RA exposure.

Key Clinical Findings

A total of 10,702 naive patient pairs and 5,577 non-naive patient pairs were included for analysis following propensity score matching. Results indicated that tirzepatide initiators exhibited higher adherence and persistence rates compared to semaglutide initiators, both in GLP-1 RA-naive and non-naive patient populations. A greater proportion of tirzepatide users achieved stringent A1c (less than 5.7%) and weight loss (greater than or equal to 15%) targets.

Sponsored content

Tirzepatide was also associated with lower T2D-related pharmacy costs per responder when these stringent targets were achieved. Specifically, for A1c less than 5.7% and weight loss greater than or equal to 15%, tirzepatide demonstrated lower costs per responder compared to semaglutide. These findings suggest a potential clinical and economic advantage for tirzepatide in achieving significant treatment outcomes in real-world T2D management.

Original Scientific Source
Journal of managed care & specialty pharmacy
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort
peptide-development

Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort

While GLP-1 and GIP receptor agonists like semaglutide and tirzepatide have revolutionized pharmacologic obesity treatment, metabolic and bariatric surgery (MBS) continues to demonstrate superior weight loss and cost-effectiveness. Current evidence shows tirzepatide outperforms semaglutide with over 20% weight...

1. 12. 2026 Read article →
Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation
peptide-development

Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved for cardiovascular risk reduction in individuals with overweight or obesity and cardiovascular disease. Whether tirzepatide, a dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonist, has similar cardiovascular benefits...

10. 11. 2026 Read article →
The Impact of Incretin-Based Therapies on Anthropometric and Metabolic Parameters in Women with Polyendocrine Metabolic Ovarian Syndrome
peptide-development

The Impact of Incretin-Based Therapies on Anthropometric and Metabolic Parameters in Women with Polyendocrine Metabolic Ovarian Syndrome

Polycystic ovary syndrome (PCOS), recently renamed polyendocrine metabolic ovarian syndrome (PMOS), affects 170 million women globally and is often accompanied by obesity and various levels of insulin resistance. Incretin-based therapies, including the glucagon-like peptide-1 (GLP-1) receptor agonists liraglutide and...

23. 10. 2026 Read article →
Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review
peptide-development

Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review

Cardiovascular-kidney-metabolic (CKM) syndrome reflects the complex interplay among cardiovascular disease, chronic kidney disease, type 2 diabetes, and obesity. GLP-1 receptor agonists and tirzepatide have emerged as important therapeutic options within CKM syndrome, although the strength and maturity of evidence...

16. 10. 2026 Read article →
Advertisement